Protein tyrosine phosphatase non-receptor type 12 (PTPN12), negatively regulated by miR-106a-5p, suppresses the progression of hepatocellular carcinoma

Liang, Zhanqiang; Li, Xingxing; Duan, Fei; Song, LiMing; Wang, Zhongzhen; Li, Xuemin; Yang, Pengsheng; Li, Liantao

doi:10.1007/s13577-021-00627-8

Cited by 6 publications

(5 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Based on these 25 intersecting genes, six FARGs (fat acidrelated genes), namely PTPN12, PLOD2, ASPH, ACLY, PGM and AMFK, were screened using the least absolute contraction and selection operator LASSO regression. except for PTPN12 as a tumor suppressor, the remaining ve FARGs played a tumor-promoting role in most cancer species PTPN12 is a member of the protein tyrosine phosphatase (PTP) family and acts as a tumor suppressor to inhibit tumor cell growth, migration and invasion in a variety of cancers such as liver, bladder and renal cell carcinomas (Liang et al, 2022). PLOD2 is a member of the PLOD family (PLOD1, PLOD2, PLOD3) and encodes a speci c protein that mediates(ChangForde & Lai, 2019).…”

Section: Discussionmentioning

confidence: 99%

Novel fatty acid metabolism biomarkers of immunotherapy response in cervical cancer

Ran

Zhang

Chen

et al. 2023

Preprint

View full text Add to dashboard Cite

Fatty acid metabolism abnormalities played an important role in cervical cancer, and current tumor stage has entered the molecular era, which determined the genomic characteristics and prognosis of cancer more precisely than the traditional TNM stage. However, molecular typing on cervical cancer based on fatty acid metabolism has not yet been unclear. Here we downloaded the gene set of fatty acid metabolism from the MSigDB database and classified cervical cancer into three independent genomic stage types-C1, C2 and C3, by extracting the expression in TCGA. Kaplan-Meier survival analysis showed significant survival differences among the three (p < 0.05), and MCPcounter analysis showed that CD8+ T-cell infiltration was more in C3, which had the best prognosis. The MCPcounter analysis showed more CD8+ T-cell infiltration in the C3 type with the best prognosis and more fibroblast infiltration in the C1 type with the worst prognosis (p < 0.05). WGCNA analysis was performed on the three molecular typologies to identify the best correlated blue modules, identify the co-expressed genes in which the association was greater than 0.3, and take the intersection with the differential genes of the three molecular typologies. A novel prognostic model for fatty acid metabolism genomics was developed. Survival analysis showed better survival differences in this model with higher immune and stromal scores in the low-risk group. 31 genes in the model were negatively correlated with immune checkpoints overall. For immunotherapy efficacy analysis, the immunotherapy efficacy was higher in the low-risk group than in the high-risk group in IPS score, and the immune dysfunction level was higher in the low-risk group than in the high-risk group in the TIDE algorithm, whereas the immune escape ability was higher in the high-risk group than in the low-risk group, and the immunotherapy level was higher in the high-risk group than in the low-risk group overall (p < 0.05). Mechanistically, the high-risk group was mainly enriched in the pathways of intercellular interaction, cell-matrix remodeling, angiogenesis, and epithelial-mesenchymal transition. In conclusion, the prognostic model of cervical cancer constructed based on the molecular typing of fatty acids metabolism could predict the prognosis and immunotherapy of the patients with cervical cancer.

show abstract

Section: Discussionmentioning

confidence: 99%

Novel fatty acid metabolism biomarkers of immunotherapy response in cervical cancer

Ran

Zhang

Chen

et al. 2023

Preprint

View full text Add to dashboard Cite

show abstract

“…Protein tyrosine phosphatase non-receptor type 12 (PTPN12) is a member of the protein tyrosine phosphatase (PTP) family, regulating cell growth, differentiation and migration. Liang et al [51] observed that PTPN12 was downregulated in the HCC tissue of 45 HCC patients compared to the corresponding adjacent tissues. Moreover, the expression of PTPN12 was associated with a larger tumor size and the extent of lymph node metastasis.…”

Section: Mirnasmentioning

confidence: 99%

Targeting Non-Coding RNAs for the Development of Novel Hepatocellular Carcinoma Therapeutic Approaches

et al. 2023

View full text Add to dashboard Cite

Hepatocellular carcinoma (HCC) remains a global health challenge, representing the third leading cause of cancer deaths worldwide. Although therapeutic advances have been made in the few last years, the prognosis remains poor. Thus, there is a dire need to develop novel therapeutic strategies. In this regard, two approaches can be considered: (1) the identification of tumor-targeted delivery systems and (2) the targeting of molecule(s) whose aberrant expression is confined to tumor cells. In this work, we focused on the second approach. Among the different kinds of possible target molecules, we discuss the potential therapeutic value of targeting non-coding RNAs (ncRNAs), which include micro interfering RNAs (miRNAs), long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs). These molecules represent the most significant RNA transcripts in cells and can regulate many HCC features, including proliferation, apoptosis, invasion and metastasis. In the first part of the review, the main characteristics of HCC and ncRNAs are described. The involvement of ncRNAs in HCC is then presented over five sections: (a) miRNAs, (b) lncRNAs, (c) circRNAs, (d) ncRNAs and drug resistance and (e) ncRNAs and liver fibrosis. Overall, this work provides the reader with the most recent state-of-the-art approaches in this field, highlighting key trends and opportunities for more advanced and efficacious HCC treatments.

show abstract

“…In a recent study by Liang et al, downregulation of protein tyrosine phosphatase non-receptor type 12 (PTPN12) in HCC was linked to miR-106a overexpression followed by a significant increase in the proliferation, invasion, and migration of tumor cells [ 110 ].…”

Section: Mir-106a: Dysregulation In Cancersmentioning

confidence: 99%

Overview of miR-106a Regulatory Roles: from Cancer to Aging

Daneshpour

Ghadimi-Daresajini

2023

Bioengineering

View full text Add to dashboard Cite

MicroRNAs (miRNAs) comprise a class of non-coding RNA with extensive regulatory functions within cells. MiR-106a is recognized for its super-regulatory roles in vital processes. Hence, the analysis of its expression in association with diseases has attracted considerable attention for molecular diagnosis and drug development. Numerous studies have investigated miR-106 target genes and shown that this miRNA regulates the expression of some critical cell cycle and apoptosis factors, suggesting miR-106a as an ideal diagnostic and prognostic biomarker with therapeutic potential. Furthermore, the reported correlation between miR-106a expression level and cancer drug resistance has demonstrated the complexity of its functions within different tissues. In this study, we have conducted a comprehensive review on the expression levels of miR-106a in various cancers and other diseases, emphasizing its target genes. The promising findings surrounding miR-106a suggest its potential as a valuable biomolecule. However, further validation assessments and overcoming existing limitations are crucial steps before its clinical implementation can be realized.

show abstract

Protein tyrosine phosphatase non-receptor type 12 (PTPN12), negatively regulated by miR-106a-5p, suppresses the progression of hepatocellular carcinoma

Cited by 6 publications

References 34 publications

Novel fatty acid metabolism biomarkers of immunotherapy response in cervical cancer

Novel fatty acid metabolism biomarkers of immunotherapy response in cervical cancer

Targeting Non-Coding RNAs for the Development of Novel Hepatocellular Carcinoma Therapeutic Approaches

Overview of miR-106a Regulatory Roles: from Cancer to Aging

Contact Info

Product

Resources

About